

Novacyt S.A.
("Novacyt", the "Company" or the "Group")

Closure of IT-IS International

Paris, France, and Eastleigh and Manchester, UK - 8 October 2024 -Novacyt S.A. (EURO NEXX GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces the closure of its IT-IS International Limited ("IT-IS") subsidiary, effective immediately.

IT-IS, a Stokesley-based manufacturer of rapid-PCR instruments, was acquired by Novacyt in 2020 to support the Group's response to COVID-19, where it facilitated the full delivery of the Group's contracts during the period. The PCR instrumentation market has since become saturated, with IT-IS subsequently experiencing several consecutive loss-making years. IT-IS contributed £0.3m to the Group's total revenue in H1 2024 (H1 2023: £0.6m).

The closure of IT-IS is anticipated to improve the Group's EBITDA position by c. £1.0m annually. A restructuring charge of c. £0.7m is expected in connection with the closure. The entity will be treated as a discontinued operation under IFRS 5 for the 2024 financial year.

The Intellectual Property ("IP") that exists within IT-IS will be retained to allow Novacyt to continue an ongoing IP infringement dispute with Roche Diagnostics GmbH. The dispute, instigated by IT-IS, dates back over five years and is currently progressing through the German courts. The Group will provide further updates on the dispute when appropriate.

Lyn Rees, Chief Executive Officer of Novacyt, said: "The saturation of the PCR instrument market following the pandemic has put significant pressure on IT-IS. Given the subsequent losses, the Board has made the strategic decision to close the business as we continue to focus on reducing our cost base and rationalising our product and service offering. By taking this step, we are better positioning the Group for future growth and driving value for our shareholders."

"I'd like to take this opportunity to thank the entire the IT-IS team for their hard work and dedication over the years."

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

Contacts

Novacyt SA

Lyn Rees, Chief Executive Officer
Steve Gibson, Chief Financial Officer

<https://novacyt.com/investors>

Via Walbrook PR

SP Angel Corporate Finance LLP (Nominated Adviser and Broker)

+44 (0)20 3470 0470

Matthew Johnson / Charlie Bouverat (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)

Deutsche Numis (Joint Broker)

+44 (0)20 7260 1000

Freddie Barnfield / Duncan Monteith / Michael Palser

Allegra Finance (French Listing Sponsor)

+33 (1) 42 22 10 10

Rémi Durgetto / Yannick Petit

r.durgetto@allegrafinance.com / y.petit@allegrafinance.com

Walbrook PR (Financial PR & IR)

+44 (0)20 7933 8780 or novacyt@walbrookpr.com

Stephanie Cuthbert / Paul McManus /
Phillip Marriage / Alice Woodings

+44 (0)7796 794 663 / +44 (0)7980 541 893

+44 (0)7867 984 082 / +44 (0)7407 804 654

About Novacyt Group (www.novacyt.com)

Novacyt is an international molecular diagnostics company providing a broad portfolio of integrated technologies and services, primarily focused on the delivery of genomic medicine. The Company develops, manufactures, and commercialises a range of molecular assays and instrumentation to deliver workflows and services that enable seamless end-to-end solutions from sample to result across multiple sectors including human health, animal health and environmental.

The Company is divided into three business segments:

Clinical

Broad portfolio of human clinical *in vitro* diagnostic products, workflows and services focused on three therapeutic areas:

- Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy tests
- Precision Medicine: DPYD genotyping assay
- Infectious Diseases: Winterplex, multiplex winter respiratory PCR panel

Instrumentation

Portfolio of next generation size selection DNA sample preparation platforms and rapid PCR machines, including:

- Ranger® Technology: automated DNA sample preparation and target enrichment technology
- MyGo: real-time quantitative PCR (qPCR) instruments

Research Use Only

Range of services for the life sciences industry:

- Design, manufacture, and supply of high-performance qPCR assays and workflows for use in human health, agriculture, veterinary and environmental, to support global health

- organisations and the research industry
- Pharmaceutical research services: whole genome sequencing (WGS) / whole exome sequencing (WES)

Novacyt is headquartered in Vélizy-Villacoublay in France with offices in the UK (in Eastleigh and Manchester), Singapore, the US and Canada and has a commercial presence in over 65 countries. The Company is listed on the London Stock Exchange's AIM market ("NCYT") and on the Paris Stock Exchange Euronext Growth ("ALNOV").

For more information, please refer to the website: www.novacyt.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seq.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCQKFBQKBDDKKK